Ads
related to: drug treatment for pulmonary fibrosis- Dosing Information
Offer Your Patients A Dosing
Schedule To Help With Treatment.
- Finding Support
Provide Patients With Access To
Their Own Personalized Care.
- Dosing Information
locationwiz.com has been visited by 10K+ users in the past month
consumerhorse.com has been visited by 100K+ users in the past month
Search results
Results from the WOW.Com Content Network
Nintedanib, sold under the brand names Ofev and Vargatef, is an oral medication used for the treatment of idiopathic pulmonary fibrosis and along with other medications for some types of non-small-cell lung cancer.
In May 2010, the U.S. Food and Drug Administration (FDA) declined to approve the use of pirfenidone for the treatment of idiopathic pulmonary fibrosis, requesting additional clinical trials. [50] In December 2010, an advisory panel to the European Medicines Agency (EMA) recommended approval of the drug. [ 8 ]
Pamrevlumab (INN; [1] development code FG-3019) is a humanized monoclonal antibody designed for the treatment of idiopathic pulmonary fibrosis and pancreatic cancer. It binds to the connective tissue growth factor (CTGF) protein. [2] This drug was developed by FibroGen, Inc. [3]
On Wednesday, Aileron Therapeutics Inc (NASDAQ; ALRN) revealed topline data from Cohort 2 of its Phase 1b trial of safety and tolerability of inhaled LTI-03 for idiopathic pulmonary fibrosis (IPF).
The once-daily triple combination treatment, called vanza triple, met the primary goals of the study's two 52-week trials and was non-inferior for lung function to Trikafta, the company's top ...
Treatment options for idiopathic pulmonary fibrosis are very limited, since no current treatment has stopped the progression of the disease. Because of this, there is no evidence that any medication can significantly help this condition, despite ongoing research trials.
Ads
related to: drug treatment for pulmonary fibrosislocationwiz.com has been visited by 10K+ users in the past month
consumerhorse.com has been visited by 100K+ users in the past month